Abstract
The quest for therapeutic specificity is implicit in all branches of medicine. In cancer treatment, cytotoxic agents, such as chemotherapy and radiotherapy, comprise the current therapeutic modality. Unfortunately, when used against most solid malignancies, their therapeutic indices are relatively low due to the significant damage they inflict on normal tissues. Furthermore, cure rates have remained essentially static over the last two decades. Specificity in killing neoplastic cells, while sparing healthy ones is therefore the only alternative approach, with several molecules qualifying as candidates for targeting therapy. Reduction of cell-cell and cell-matrix adhesion are, early tumorigenesis events also implicated in the invasive and metastatic process. The fact that abnormal adhesive marker expression is a feature commonly shared by most malignancies, along with its tendency to occur as both an early and late event in neoplastic development, makes these molecules potential candidates for antineoplastic targeted therapies. This review presents the perspectives of specific anti-adhesion molecule targeting as a possible therapeutic approach in neoplastic diseases.
Keywords: Cell adhesion, CEA, E-cadherin-catenin complex, integrins, selectins, targeted therapy
Current Pharmaceutical Design
Title: Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Volume: 12 Issue: 22
Author(s): Konstantinos N. Syrigos and Anastasios J. Karayiannakis
Affiliation:
Keywords: Cell adhesion, CEA, E-cadherin-catenin complex, integrins, selectins, targeted therapy
Abstract: The quest for therapeutic specificity is implicit in all branches of medicine. In cancer treatment, cytotoxic agents, such as chemotherapy and radiotherapy, comprise the current therapeutic modality. Unfortunately, when used against most solid malignancies, their therapeutic indices are relatively low due to the significant damage they inflict on normal tissues. Furthermore, cure rates have remained essentially static over the last two decades. Specificity in killing neoplastic cells, while sparing healthy ones is therefore the only alternative approach, with several molecules qualifying as candidates for targeting therapy. Reduction of cell-cell and cell-matrix adhesion are, early tumorigenesis events also implicated in the invasive and metastatic process. The fact that abnormal adhesive marker expression is a feature commonly shared by most malignancies, along with its tendency to occur as both an early and late event in neoplastic development, makes these molecules potential candidates for antineoplastic targeted therapies. This review presents the perspectives of specific anti-adhesion molecule targeting as a possible therapeutic approach in neoplastic diseases.
Export Options
About this article
Cite this article as:
Syrigos N. Konstantinos and Karayiannakis J. Anastasios, Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases, Current Pharmaceutical Design 2006; 12 (22) . https://dx.doi.org/10.2174/138161206777947759
DOI https://dx.doi.org/10.2174/138161206777947759 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design A Review on Recent Developments in Positron Emission Tomography Technology
Recent Patents on Medical Imaging Apoptotic and Antiproliferative Potential of GAPDH from <i>Mallotus philippensis</i> Seed on Human Lung Carcinoma: <i>In Vitro</i> and <i>In Vivo</i> Approach
Protein & Peptide Letters Adenosine and the Auditory System
Current Neuropharmacology Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity
Current Genomics Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Amyloidogenicity of p53: A Hidden Link Between Protein Misfolding and Cancer
Current Protein & Peptide Science Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe
Current Drug Metabolism Editorial Review 2017
Current Radiopharmaceuticals Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics